Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Talbot

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancerD C Talbot, I E Smith, M C Nicolson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1991
Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancerD C Talbot, I E Smith, J L Mansi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Phase II study of liarozole in advanced non-small cell lung cancerK J O'Byrne, C Han, K Mitchell, et al.
British Journal of Cancer|January 1, 1997
Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069A V Patterson, M P Saunders, E C Chinje, et al.
British Journal of Cancer|September 1, 1995
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylaseA V Patterson, H Zhang, A Moghaddam, et al.
The Journal of Pathology|May 1, 1996
Prognostic value of angiogenesis in operable non-small cell lung cancerA Giatromanolaki, M Koukourakis, K O'Byrne, et al.
International Journal of Cancer|January 8, 1998
Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancerM I Koukourakis, A Giatromanolaki, K J O'Byrne, et al.
British Journal of Cancer|February 1, 1995
Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancerP A Ellis, I E Smith, J R Hardy, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 1, 1996
Dihydropyridine receptor blockers and skeletal muscle metabolismC H Thompson, V M Macaulay, K J O'Byrne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignanciesJ P Braybrooke, E Boven, N P Bates, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancerD C Talbot, I E Smith, M C Nicolson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1991
Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancerD C Talbot, I E Smith, J L Mansi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Phase II study of liarozole in advanced non-small cell lung cancerK J O'Byrne, C Han, K Mitchell, et al.
British Journal of Cancer|January 1, 1997
Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069A V Patterson, M P Saunders, E C Chinje, et al.
British Journal of Cancer|September 1, 1995
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylaseA V Patterson, H Zhang, A Moghaddam, et al.
The Journal of Pathology|May 1, 1996
Prognostic value of angiogenesis in operable non-small cell lung cancerA Giatromanolaki, M Koukourakis, K O'Byrne, et al.
International Journal of Cancer|January 8, 1998
Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancerM I Koukourakis, A Giatromanolaki, K J O'Byrne, et al.
British Journal of Cancer|February 1, 1995
Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancerP A Ellis, I E Smith, J R Hardy, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 1, 1996
Dihydropyridine receptor blockers and skeletal muscle metabolismC H Thompson, V M Macaulay, K J O'Byrne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignanciesJ P Braybrooke, E Boven, N P Bates, et al.
Pageof 7